investorscraft@gmail.com

Intrinsic value of Intuitive Surgical, Inc. (ISRG)

Previous Close$274.49
Intrinsic Value
Upside potential
Previous Close
$274.49

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh84.21 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-09-30.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %31.0NaN
Revenue, $5710NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m3889NaN
Operating income, $m1821NaN
EBITDA, $m2153NaN
Interest expense (income), $mNaN
Earnings before tax, $m1867NaN
Tax expense, $m162NaN
Net income, $m1705NaN

BALANCE SHEET

Cash and short-term investments, $m4204NaN
Total assets, $m13555NaN
Adjusted assets (=assets-cash), $m9351NaN
Average production assets, $m2635NaN
Working capital, $m4695NaN
Total debt, $m87NaN
Total liabilities, $m1604NaN
Total equity, $m11952NaN
Debt-to-equity ratio0.007NaN
Adjusted equity ratio0.831NaN

CASH FLOW

Net income, $m1705NaN
Depreciation, amort., depletion, $m332NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m2089NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-354NaN
Free cash flow, $m2443NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m4695
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount